Unlocking the potential of T-cell metabolism reprogramming: Advancing single-cell approaches for precision immunotherapy in tumour immunity

Abstract

As single-cell RNA sequencing enables the detailed clustering of T-cell subpopulations and facilitates the analysis of T-cell metabolic states and metabolite dynamics, it has gained prominence as the preferred tool for understanding heterogeneous cellular metabolism. Furthermore, the synergistic or inhibitory effects of various metabolic pathways within T cells in the tumour microenvironment are coordinated, and increased activity of specific metabolic pathways generally corresponds to increased functional activity, leading to diverse T-cell behaviours related to the effects of tumour immune cells, which shows the potential of tumour-specific T cells to induce persistent immune responses. A holistic understanding of how metabolic heterogeneity governs the immune function of specific T-cell subsets is key to obtaining field-level insights into immunometabolism. Therefore, exploring the mechanisms underlying the interplay between T-cell metabolism and immune functions will pave the way for precise immunotherapy approaches in the future, which will empower us to explore new methods for combating tumours with enhanced efficacy.

Keywords

immunotherapy / metabolic reprogramming / single-cell RNA sequencing / T-cell metabolism / tumour immunity

References

[1] Kempkes RWM, Joosten I, Koenen HJPM, He X. Metabolic pathways involved in regulatory T cell functionality. Front Immunol. 2019;10:2839.

[2] Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473-488.

[3] Iwahori K. Cytotoxic CD8(+) lymphocytes in the tumor microenvironment. Adv Exp Med Biol. 2020;1224:53-62.

[4] Lee HL, Jang JW, Lee SW, et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep. 2019;9(1):3260.

[5] Leitner BP, Givechian KB, Ospanova S, Beisenbayeva A, Politi K, Perry RJ. Multimodal analysis suggests differential immuno-metabolic crosstalk in lung squamous cell carcinoma and adenocarcinoma. NPJ Precision Oncol. 2022;6(1):8.

[6] Chang CH, Qiu J, O'Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229-1241.

[7] Yan Y, Huang L, Liu Y, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022;15(1):104.

[8] Soriano-Baguet L, Brenner D. Metabolism and epigenetics at the heart of T cell function. Trends Immunol. 2023;44(3):231-244.

[9] Cardona EN, Walsh AJ. Identification of rare cell populations in autofluorescence lifetime image data. Cytometry Part A. 2022;101(6):497-506.

[10] Chang CH, Curtis JD, Maggi LB, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153(6):1239-1251.

[11] Ye M, Li X, Chen L, et al. A high-throughput sequencing data-based classifier reveals the metabolic heterogeneity of hepatocellular carcinoma. Cancers. 2023;15(3):592.

[12] Liu YN, Yang JF, Huang DJ, et al. Hypoxia induces mitochondrial defect that promotes T cell exhaustion in tumor microenvironment through MYC-regulated pathways. Front Immunol. 2020;11:1906.

[13] Lee J, Walsh MC, Hoehn KL, James DE, Wherry EJ, Choi Y. Regulator of fatty acid metabolism, acetyl coenzyme A carboxylase 1, controls T cell immunity. J Immunol. 2014;192(7):3190-3199.

[14] Angelin A, Gil-de-Gómez L, Dahiya S, et al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. 2017;25(6):1282-1293.e7.

[15] Gong L, Luo J, Zhang Y, et al. Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction. Nat Commun. 2023;14(1):1912.

[16] Tyrakis PA, Palazon A, Macias D, et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature. 2016;540(7632):236-241.

[17] Bian Y, Li W, Kremer DM, et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature. 2020;585(7824):277-282.

[18] Rossi A, Pacella I, Piconese S. RNA flow cytometry for the study of T cell metabolism. Int J Mol Sci. 2021;22(8):3906.

[19] Zhang T, Warden AR, Li Y, Ding X. Progress and applications of mass cytometry in sketching immune landscapes. Clin Transl Med. 2020;10(6):e206.

[20] Hedlund E, Deng Q. Single-cell RNA sequencing: technical advancements and biological applications. Mol Aspects Med. 2018;59:36-46.

[21] Wang Y, Navin NE. Advances and applications of single-cell sequencing technologies. Mol Cell. 2015;58(4):598-609.

[22] Khozyainova AA, Valyaeva AA, Arbatsky MS, et al. Complex analysis of single-cell RNA sequencing data. Biochem Moscow. 2023;88(2):231-252.

[23] Xie S, Cai Y, Chen D, et al. Single-cell transcriptome analysis reveals heterogeneity and convergence of the tumor microenvironment in colorectal cancer. Front Immunol. 2022;13:1003419.

[24] He W, Hu Y, Chen D, et al. Hepatocellular carcinoma-infiltrating γδ T cells are functionally defected and allogenic Vδ2(+) γδ T cell can be a promising complement. Clin Transl Med. 2022;12(4):e800.

[25] Huang M, Xiong D, Pan J, et al. Targeting glutamine metabolism to enhance immunoprevention of EGFR-driven lung cancer. Adv Sci. 2022;9(26):e2105885.

[26] Masopust D, Schenkel JM. The integration of T cell migration, differentiation and function. Nat Rev Immunol. 2013;13(5):309-320.

[27] Aoki H, Shichino S, Matsushima K, Ueha S. Revealing clonal responses of tumor-reactive T-cells through T cell receptor repertoire analysis. Front Immunol. 2022;13:807696.

[28] Masopust D, Choo D, Vezys V, et al. Dynamic T cell migration program provides resident memory within intestinal epithelium. J Exp Med. 2010;207(3):553-564.

[29] Schenkel JM, Masopust D. Tissue-resident memory T cells. Immunity. 2014;41(6):886-897.

[30] Ji F, Chen L, Chen Z, Luo B, Wang Y, Lan X. TCR repertoire and transcriptional signatures of circulating tumour-associated T cells facilitate effective non-invasive cancer detection. Clin Transl Med. 2022;12(9):e853.

[31] Pauken KE, Shahid O, Lagattuta KA, et al. Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment. J Exp Med. 2021;218(4):e20200920.

[32] Zhang Z, Xiong D, Wang X, Liu H, Wang T. Mapping the functional landscape of T cell receptor repertoires by single-T cell transcriptomics. Nat Methods. 2021;18(1):92-99.

[33] Wei J, Hu M, Huang K, Lin S, Du H. Roles of proteoglycans and glycosaminoglycans in cancer development and progression. Int J Mol Sci. 2020;21(17):5983.

[34] Zhang N, Zhang H, Liu Z, et al. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Prolif. 2023;56(4):e13409.

[35] Allard B, Allard D, Buisseret L, Stagg J. The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol. 2020;17(10):611-629.

[36] Slaats J, Wagena E, Smits D, et al. Adenosine A2a receptor antagonism restores additive cytotoxicity by cytotoxic T cells in metabolically perturbed tumors. Cancer Immunol Res. 2022;10(12):1462-1474.

[37] Beckermann KE, Hongo R, Ye X, et al. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight. 2020;5(16):e138729.

[38] Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33(4):547-562.

[39] Sun Y, Wu L, Zhong Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma. Cell. 2021;184(2):404-421.e16.

[40] Zhang Y, Chen H, Mo H, et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell. 2021;39(12):1578-1593.e8.

[41] Huang XZ, Pang MJ, Li JY, et al. Single-cell sequencing of ascites fluid illustrates heterogeneity and therapy-induced evolution during gastric cancer peritoneal metastasis. Nat Commun. 2023;14(1):822.

[42] Leone RD, Powell JD. Metabolism of immune cells in cancer. Nat Rev Cancer. 2020;20(9):516-531.

[43] Han J, Khatwani N, Searles TG, Turk MJ, Angeles CV. Memory CD8+ T cell responses to cancer. Semin Immunol. 2020;49:101435.

[44] Rahimi RA, Luster AD. Redefining memory T cell subsets. Trends Immunol. 2020;41(8):645-648.

[45] Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211(1):81-92.

[46] Reiner SL, Sallusto F, Lanzavecchia A. Division of labor with a workforce of one: challenges in specifying effector and memory T cell fate. Science. 2007;317(5838):622-625.

[47] Sabatino M, Hu J, Sommariva M, et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood. 2016;128(4):519-528.

[48] Arcangeli S, Falcone L, Camisa B, et al. Next-generation manufacturing protocols enriching TSCM CAR T cells can overcome disease-specific T cell defects in cancer patients. Front Immunol. 2020;11:1217.

[49] Costa Del Amo P, Lahoz-Beneytez J, Boelen L, et al. Human TSCM cell dynamics in vivo are compatible with long-lived immunological memory and stemness. PLoS Biol. 2018;16(6):e2005523.

[50] Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514-524.

[51] Veliça P, Zech M, Henson S, et al. Genetic regulation of fate decisions in therapeutic T cells to enhance tumor protection and memory formation. Cancer Res. 2015;75(13):2641-2652.

[52] Zhang L, Romero P. Metabolic control of CD8+ T cell fate decisions and antitumor immunity. Trends Mol Med. 2018;24(1):30-48.

[53] Fernández-García J, Franco F, Parik S, et al. CD8(+) T cell metabolic rewiring defined by scRNA-seq identifies a critical role of ASNS expression dynamics in T cell differentiation. Cell Rep. 2022;41(7):111639.

[54] Deng W, Ma Y, Su Z, et al. Single-cell RNA-sequencing analyses identify heterogeneity of CD8(+) T cell subpopulations and novel therapy targets in melanoma. Mol Therapy Oncolytics. 2021;20:105-118.

[55] Levine LS, Hiam-Galvez KJ, Marquez DM, et al. Single-cell analysis by mass cytometry reveals metabolic states of early-activated CD8+ T cells during the primary immune response. Immunity. 2021;54(4):829-844.e5.

[56] Zhang H, Tang K, Ma J, et al. Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8+ T-cell memory development. Nat Cell Biol. 2020;22(1):18-25.

[57] Wherry EJ, Teichgräber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol. 2003;4(3):225-234.

[58] Xu Y, Chaudhury A, Zhang M, et al. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest. 2016;126(7):2678-2688.

[59] Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol. 2012;24(4):476-481.

[60] Krall AS, Mullen PJ, Surjono F, et al. Asparagine couples mitochondrial respiration to ATF4 activity and tumor growth. Cell Metab. 2021;33(5):1013-1026.e6.

[61] Noree C, Monfort E, Shotelersuk V. Human asparagine synthetase associates with the mitotic spindle. Biol Open. 2018;7(12):bio038307.

[62] Flynn JK, Gorry PR. Stem memory T cells (TSCM)—their role in cancer and HIV immunotherapies. Clin Transl Immunol. 2014;3(7):e20.

[63] Lin R, Zhang H, Yuan Y, et al. Fatty acid oxidation controls CD8+ tissue-resident memory T-cell survival in gastric adenocarcinoma. Cancer Immunol Res. 2020;8(4):479-492.

[64] Scholz G, Jandus C, Zhang L, et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. EBioMedicine. 2016;4:50-61.

[65] Huang H, Zhou P, Wei J, et al. In vivo CRISPR screening reveals nutrient signalling processes underpinning CD8+ T cell fate decisions. Cell. 2021;184(5):1245-1261.e21.

[66] Blanco R, Gómez de Cedrón M, Gámez-Reche L, et al. The chemokine receptor CCR5 links memory CD4+ T cell metabolism to T cell antigen receptor nanoclustering. Front Immunol. 2021;12:722320.

[67] Riesenberg BP, Hunt EG, Tennant MD, et al. Stress-mediated attenuation of translation undermines T cell tumor control. bioRxiv. 2022. 2022.01.31.478547.

[68] Liu X, Xu X, Wu Z, et al. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers. Front Immunol. 2022;13:961350.

[69] Biswas SK. Metabolic reprogramming of immune cells in cancer progression. Immunity. 2015;43(3):435-449.

[70] Xu W, Powell JD. Peeking under the hood of naive T cells. Cell Metab. 2018;28(6):801-802.

[71] Walsh AJ, Mueller KP, Tweed K, et al. Classification of T-cell activation via autofluorescence lifetime imaging. Nat Biomed Eng. 2021;5(1):77-88.

[72] Ringel AE, Drijvers JM, Baker GJ, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 2020;183(7):1848-1866.e26.

[73] Qian J, Olbrecht S, Boeckx B, et al. A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling. Cell Res. 2020;30(9):745-762.

[74] Vidal M, Fraga M, Llerena F, et al. Analysis of tumor-infiltrating T-cell transcriptomes reveal a unique genetic signature across different types of cancer. Int J Mol Sci. 2022;23(19):11065.

[75] Li D, Yu H, Hu J, et al. Comparative profiling of single-cell transcriptome reveals heterogeneity of tumor microenvironment between solid and acinar lung adenocarcinoma. J Transl Med. 2022;20(1):423.

[76] Wang Z, Dong C. Gluconeogenesis in cancer: function and regulation of PEPCK, FBPase, and G6Pase. Trends Cancer. 2019;5(1):30-45.

[77] Desdín-Micó G, Soto-Heredero G, Aranda JF, et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 2020;368(6497):1371-1376.

[78] Hartmann FJ, Mrdjen D, McCaffrey E, et al. Single-cell metabolic profiling of human cytotoxic T cells. Nat Biotechnol. 2021;39(2):186-197.

[79] Bengsch B, Johnson AL, Kurachi M, et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T cell exhaustion. Immunity. 2016;45(2):358-373.

[80] Vardhana SA, Hwee MA, Berisa M, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21(9):1022-1033.

[81] Vahedi S, Chueh FY, Dutta S, Chandran B, Yu CL. Nuclear lymphocyte-specific protein tyrosine kinase and its interaction with CR6-interacting factor 1 promote the survival of human leukemic T cells. Oncol Rep. 2015;34(1):43-50.

[82] Vahedi S, Chueh FY, Chandran B, Yu CL. Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation. BMC Cancer. 2015;15:551.

[83] Jiang Y, Xiang Y, Lin C, et al. Multifunctions of CRIF1 in cancers and mitochondrial dysfunction. Front Oncol. 2022;12:1009948.

[84] Laukkanen S, Veloso A, Yan C, et al. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140(17):1891-1906.

[85] Meng Y, Huang T, Chen X, Lu Y. A comprehensive analysis of the expression and regulation network of lymphocyte-specific protein tyrosine kinase in breast cancer. Transl Cancer Res. 2021;10(3):1519-1536.

[86] Liu F, Liu W, Zhou S, et al. Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. J Immunother Cancer. 2020;8(2):e000501.

[87] Zhang Y, Vu T, Palmer DC, et al. A T cell resilience model associated with response to immunotherapy in multiple tumor types. Nat Med. 2022;28(7):1421-1431.

[88] Liu J, Shen H, Gu W, et al. Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma. Front Immunol. 2022;13:960738.

[89] Sievers C, Craveiro M, Friedman J, et al. Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer. Cancer Cell. 2023;41(5):887-902.e5.

[90] Pacheco MP, Ji J, Prohaska T, García MM, Sauter T. scFASTCORMICS: a contextualization algorithm to reconstruct metabolic multi-cell population models from single-cell RNAseq data. Metabolites. 2022;12(12):1211.

[91] Lv J, Sun H, Gong L, et al. Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma. Front Immunol. 2022;13:1077768.

[92] Zhang Y, Kurupati R, Liu L, et al. Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell. 2017;32(3):377-391.e9.

[93] Cribioli E, Giordano Attianese GMP, Ginefra P, et al. Enforcing GLUT3 expression in CD8+ T cells improves fitness and tumor control by promoting glucose uptake and energy storage. Front Immunol. 2022;13:976628.

[94] Hudson WH, Wieland A. Technology meets TILs: deciphering T cell function in the omics era. Cancer Cell. 2023;41(1):41-57.

[95] Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23(5):295-316.

[96] Simoni Y, Becht E, Fehlings M, et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557(7706):575-579.

[97] Oliveira G, Stromhaug K, Klaeger S, et al. Phenotype, specificity and avidity of antitumour CD8+ T cells in melanoma. Nature. 2021;596(7870):119-125.

[98] Shim CH, Cho S, Shin YM, Choi JM. Emerging role of bystander T cell activation in autoimmune diseases. BMB Rep. 2022;55(2):57-64.

[99] Liu Z, Li JP, Chen M, et al. Detecting tumor antigen-specific T cells via interaction dependent fucosyl-biotinylation. Cell. 2020;183(4):1117-1133.e19.

[100] Takahashi H, Nomura H, Iriki H, et al. Cholesterol 25-hydroxylase is a metabolic switch to constrain T cell-mediated inflammation in the skin. Sci Immunol. 2021;6(64):eabb6444.

[101] Ahrends T, Borst J. The opposing roles of CD4+ T cells in anti-tumour immunity. Immunology. 2018;154(4):582-592.

[102] Oh DY, Fong L. Cytotoxic CD4+ T cells in cancer: expanding the immune effector toolbox. Immunity. 2021;54(12):2701-2711.

[103] Ahmadzadeh M, Pasetto A, Jia L, et al. Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity. Sci Immunol. 2019;4(31):eaao4310.

[104] Wang F, Zhang Y, Hao Y, et al. Characterizing the metabolic and immune landscape of non-small cell lung cancer reveals prognostic biomarkers through omics data integration. Front Cell Dev Biol. 2021;9:702112.

[105] Muri J, Kopf M. Redox regulation of immunometabolism. Nat Rev Immunol. 2021;21(6):363-381.

[106] Salmon AJ, Shavkunov AS, Miao Q, et al. BHLHE40 regulates the T-cell effector function required for tumor microenvironment remodeling and immune checkpoint therapy efficacy. Cancer Immunol Res. 2022;10(5):597-611.

[107] Decking SM, Bruss C, Babl N, et al. LDHB overexpression can partially overcome T cell inhibition by lactic acid. Int J Mol Sci. 2022;23(11):5970.

[108] Kim MJ, Kim K, Park HJ, et al. Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells. Nat Immunol. 2023;24(1):148-161.

[109] Song BS, Moon JS, Tian J, et al. Mitoribosomal defects aggravate liver cancer via aberrant glycolytic flux and T cell exhaustion. J Immunother Cancer. 2022;10(5):e004337.

[110] Lu Y, Li Y, Liu Q, et al. MondoA-thioredoxin-interacting protein axis maintains regulatory T-cell identity and function in colorectal cancer microenvironment. Gastroenterology. 2021;161(2):575-591.e16.

[111] Bayik D, Lathia JD. Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer. 2021;21(8):526-536.

[112] Araujo L, Khim P, Mkhikian H, Mortales CL, Demetriou M. Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation. eLife. 2017;6:e21330.

[113] Zhao X, Di Q, Liu H, et al. MEF2C promotes M1 macrophage polarization and Th1 responses. Cell Mol Immunol. 2022;19(4):540-553.

[114] Johnson MO, Wolf MM, Madden MZ, et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell. 2018;175(7):1780-1795.e19.

[115] Gao T, Díaz-Hirashi Z, Verdeguer F. Metabolic signaling into chromatin modifications in the regulation of gene expression. Int J Mol Sci. 2018;19(12):4108.

[116] Klysz D, Tai X, Robert PA, et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci Signal. 2015;8(396):ra97.

[117] Su H, Liang Z, Weng S, et al. miR-9-5p regulates immunometabolic and epigenetic pathways in β-glucan-trained immunity via IDH3α. JCI Insight. 2021;6(9):e144260.

[118] Yan Y, Huang L, Liu Y, et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol. 2022;15:104.

[119] Kurniawan H, Franchina DG, Guerra L, et al. Glutathione restricts serine metabolism to preserve regulatory T cell function. Cell Metab. 2020;31(5):920-936.e7.

[120] Ke X, Zhang S, Xu J, et al. Non-small-cell lung cancer-induced immunosuppression by increased human regulatory T cells via Foxp3 promoter demethylation. Cancer Immunol Immunother. 2016;65(5):587-599.

[121] Xu T, Stewart KM, Wang X, et al. Metabolic control of TH17/iTreg balance by an epigenetic mechanism. Nature. 2017;548(7666):228-233.

[122] de Candia P, Procaccini C, Russo C, Lepore MT, Matarese G. Regulatory T cells as metabolic sensors. Immunity. 2022;55(11):1981-1992.

[123] Hu Y, Xu C, Ren J, et al. Exposure to tobacco smoking induces a subset of activated tumor-resident Tregs in non-small cell lung cancer. Transl Oncol. 2022;15(1):101261.

[124] Wang Y, Huang T, Gu J, Lu L. Targeting the metabolism of tumor-infiltrating regulatory T cells. Trends Immunol. 2023;44(8):598-612.

[125] Gu M, Zhou X, Sohn JH, et al. NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity. Nat Immunol. 2021;22(2):193-204.

[126] Cari L, De Rosa F, Nocentini G, Riccardi C. Context-dependent effect of glucocorticoids on the proliferation, differentiation, and apoptosis of regulatory T cells: a review of the empirical evidence and clinical applications. Int J Mol Sci. 2019;20(5):1142.

[127] Rivadeneira DB, DePeaux K, Wang Y, et al. Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating T cell metabolism and promote tumor clearance. Immunity. 2019;51(3):548-560.e4.

[128] de Candia P, Prattichizzo F, Garavelli S, Alviggi C, La Cava A, Matarese G. The pleiotropic roles of leptin in metabolism, immunity, and cancer. J Exp Med. 2021;218(5):e20191593.

[129] Wang Z, Dai Z, Zhang H, et al. Tumor-secreted lactate contributes to an immunosuppressive microenvironment and affects CD8 T-cell infiltration in glioblastoma. Front Immunol. 2023;14:894853.

[130] Wang ZH, Zhang P, Peng WB, et al. Altered phenotypic and metabolic characteristics of FOXP3(+)CD3(+)CD56(+) natural killer T (NKT)-like cells in human malignant pleural effusion. Oncoimmunology. 2023;12(1):2160558.

[131] Kumagai S, Koyama S, Itahashi K, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40(2):201-218.e9.

[132] Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. 2021;591(7851):645-651.

[133] Weinberg SE, Singer BD, Steinert EM, et al. Mitochondrial complex III is essential for suppressive function of regulatory T cells. Nature. 2019;565(7740):495-499.

[134] Mayassi T, Barreiro LB, Rossjohn J, Jabri B. A multilayered immune system through the lens of unconventional T cells. Nature. 2021;595(7868):501-510.

[135] Ruf B, Greten TF, Korangy F. Innate lymphoid cells and innate-like T cells in cancer—at the crossroads of innate and adaptive immunity. Nat Rev Cancer. 2023;23(6):351-371.

[136] Blanco DB, Chapman NM, Raynor JL, et al. PTEN directs developmental and metabolic signaling for innate-like T cell fate and tissue homeostasis. Nat Cell Biol. 2022;24(11):1642-1654.

[137] Raynor JL, Liu C, Dhungana Y, et al. Hippo/Mst signaling coordinates cellular quiescence with terminal maturation in iNKT cell development and fate decisions. J Exp Med. 2020;217(6):e20191157.

[138] Gao Z, Bai Y, Lin A, et al. Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. Mol Cancer. 2023;22(1):31.

[139] Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619-634.

[140] Reis BS, Darcy PW, Khan IZ, et al. TCR-Vγδ usage distinguishes protumor from antitumor intestinal γδ T cell subsets. Science. 2022;377(6603):276-284.

[141] Lopes N, McIntyre C, Martin S, et al. Distinct metabolic programs established in the thymus control effector functions of γδ T cell subsets in tumor microenvironments. Nat Immunol. 2021;22(2):179-192.

[142] Chen Xu, Cai Y, Hu X, et al. Differential metabolic requirement governed by transcription factor c-Maf dictates innate γδT17 effector functionality in mice and humans. Sci Adv. 2022;8(21):eabm9120.

[143] Sun C, Shou P, Du H, et al. THEMIS-SHP1 recruitment by 4–1BB tunes LCK-mediated priming of chimeric antigen receptor-redirected T cells. Cancer Cell. 2020;37(2):216-225.e6.

[144] Hu B, Jadhav RR, Gustafson CE, et al. Distinct age-related epigenetic signatures in CD4 and CD8 T cells. Front Immunol. 2020;11:585168.

[145] Cai X, Li H, Wang M, et al. mTOR participates in the formation, maintenance, and function of memory CD8+ T cells regulated by glycometabolism. Biochem Pharmacol. 2022;204:115197.

[146] Afzal O, Altamimi ASA, Mubeen B, et al. mTOR as a potential target for the treatment of microbial infections, inflammatory bowel diseases, and colorectal cancer. Int J Mol Sci. 2022;23(20):12470.

[147] Liu Z, Liang Q, Ren Y, et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther. 2023;8(1):200.

[148] Wang F, Zhang Y, Yu X, et al. ZFP91 disturbs metabolic fitness and antitumor activity of tumor-infiltrating T cells. J Clin Invest. 2021;131(19):e144318.

[149] Zhang Z, Li F, Tian Y, et al. Metformin enhances the antitumor activity of CD8+ T lymphocytes via the AMPK–miR-107–Eomes–PD-1 pathway. J Immunol. 2020;204(9):2575-2588.

[150] Taves MD, Ashwell JD. Glucocorticoids in T cell development, differentiation and function. Nat Rev Immunol. 2021;21(4):233-243.

[151] Wang G, Sun J, Zhang J, et al. Single-cell transcriptional profiling uncovers the association between EOMES(+)CD8(+) T cells and acquired EGFR-TKI resistance. Drug Resist Updat. 2023;66:100910.

[152] Chen C, Liu J, Chen Y, et al. Application of ATAC-seq in tumor-specific T cell exhaustion. Cancer Gene Ther. 2023;30(1):1-10.

[153] Gou D, Liu R, Shan X, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023;133(13):e161713.

[154] Geiger R, Rieckmann JC, Wolf T, et al. L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity. Cell. 2016;167(3):829-842.e13.

[155] Luo L, Li X, Zhang J, et al. Enhanced immune memory through a constant photothermal-metabolism regulation for cancer prevention and treatment. Biomaterials. 2021;270:120678.

[156] Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21(3):145-161.

[157] Kawalekar OU, O'Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380-390.

[158] Lichtman EI, Dotti G. Chimeric antigen receptor T-cells for B-cell malignancies. Transl Res. 2017;187:59-82.

[159] Zhong G, Wang Q, Wang Y, et al. scRNA-seq reveals ATPIF1 activity in control of T cell antitumor activity. Oncoimmunology. 2022;11(1):2114740.

[160] Liu Y, An L, Huang R, et al. Strategies to enhance CAR-T persistence. Biomark Res. 2022;10(1):86.

[161] Zheng W, O'Hear CE, Alli R. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells. Leukemia. 2018;32(5):1157-1167.

[162] Huang X, Sun T, Wang J, et al. Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer. Cancer Res. 2023;83(14):2358-2371.

[163] Yu Q, Tu H, Yin X, et al. Targeting glutamine metabolism ameliorates autoimmune hepatitis via inhibiting T cell activation and differentiation. Front Immunol. 2022;13:880262.

[164] Best SA, Gubser PM, Sethumadhavan S, et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab. 2022;34(6):874-887.e6.

[165] Cheng SC, Quintin J, Cramer RA, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345(6204):1250684.

[166] Vadlakonda L, Dash A, Pasupuleti M, Anil Kumar K, Reddanna P. The paradox of Akt–mTOR interactions. Front Oncol. 2013;3:165.

[167] Sorrenti V, Benedetti F, Buriani A, et al. Immunomodulatory and antiaging mechanisms of resveratrol, rapamycin, and metformin: focus on mTOR and AMPK signaling networks. Pharmaceuticals (Basel). 2022;15(8):912.

[168] Langdon S, Hughes A, Taylor MA, et al. Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity. Oncoimmunology. 2018;7(8):e1458810.

[169] Delgoffe GM, Pollizzi KN, Waickman AT, et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol. 2011;12(4):295-303.

[170] Chatterjee S, Chakraborty P, Daenthanasanmak A, et al. Targeting PIM kinase with PD1 inhibition improves immunotherapeutic anti-tumor T cell response. Clin Cancer Res. 2019;25(3):1036-1049.

[171] Kunisada Y, Eikawa S, Tomonobu N, et al. Attenuation of CD4+CD25+ regulatory T cells in the tumor microenvironment by metformin, a type 2 diabetes drug. EBioMedicine. 2017;25:154-164.

[172] Wang S, Lin Y, Xiong X, et al. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial. Clin Cancer Res. 2020;26(18):4921-4932.

[173] Finisguerra V, Dvorakova T, Formenti M, et al. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression. J Immunother Cancer. 2023;11(5):e005719.

[174] Endo Y, Onodera A, Obata-Ninomiya K, et al. ACC1 determines memory potential of individual CD4+ T cells by regulating de novo fatty acid biosynthesis. Nat Metab. 2019;1(2):261-275.

[175] Rodríguez-Perea AL, Rojas M, Velilla-Hernández PA. High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells. Clin Exp Immunol. 2019;196(2):237-248.

[176] Martins Nascentes Melo L, Herrera-Rios D, Hinze D, et al. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. J Immunother Cancer. 2023;11(4):e004150.

[177] Pandit M, Kil YS, Ahn JH, et al. Methionine consumption by cancer cells drives a progressive upregulation of PD-1 expression in CD4 T cells. Nat Commun. 2023;14(1):2593.

[178] Sosnowska A, Chlebowska-Tuz J, Matryba P, et al. Inhibition of arginase modulates T-cell response in the tumor microenvironment of lung carcinoma. OncoImmunology. 2021;10(1):1956143.

[179] Perrot I, Michaud HA, Giraudon-Paoli M, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411-2425.e9.

[180] Stirling ER, Terabe M, Wilson AS, et al. Targeting the CD47/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response. J Immunother Cancer. 2022;10(11):e004712.

[181] Tao H, Qian P, Wang F, Yu H, Guo Y. Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in an esophageal squamous cell cancer preclinical model. Oncol Res. 2017;25(9):1579-1587.

[182] Willingham SB, Ho PY, Hotson A, et al. A2AR antagonism with CPI-444 induces antitumor responses and augments efficacy to anti-PD-(L)1 and anti-CTLA-4 in preclinical models. Cancer Immunol Res. 2018;6(10):1136-1149.

[183] Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20(12):739-755.

[184] Salter AI, Ivey RG, Kennedy JJ, et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 2018;11(544):eaat6753.

[185] Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21(6):581-590.

[186] Menk AV, Scharping NE, Rivadeneira DB, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215(4):1091-1100.

[187] Lau E, Kwong G, Fowler TW, et al. Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness. Cytotherapy. 2023;25(7):750-762.

[188] Ye L, Park JJ, Peng L, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 2022;34(4):595-614.e14.

[189] Huang Y, Si X, Shao M, Teng X, Xiao G, Huang H. Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. J Hematol Oncol. 2022;15:38.

[190] Lontos K, Wang Y, Joshi SK, et al. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors. J Immunother Cancer. 2023;11(3):e006522.

[191] Abken H. Costimulation engages the gear in driving CARs. Immunity. 2016;44(2):214-216.

[192] Mohrin M, Shin J, Liu Y, et al. A mitochondrial UPR-mediated metabolic checkpoint regulates hematopoietic stem cell aging. Science. 2015;347(6228):1374-1377.

[193] Zhang Q, Ding J, Sun S, et al. Akt inhibition at the initial stage of CAR-T preparation enhances the CAR-positive expression rate, memory phenotype and in vivo efficacy. Am J Cancer Res. 2019;9(11):2379-2396.

[194] Huang Y, Chen Z, Lu T, et al. HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer. J Exp Clin Cancer Res. 2021;40(1):398.

[195] Tang N, Cheng C, Zhang X, et al. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020;5(4):e133977.

[196] Stüber T, Monjezi R, Wallstabe L, et al. Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. J Immunother Cancer. 2020;8(1):e000676.

[197] Kloss CC, Lee J, Zhang A, et al. Dominant-negative TGF-β receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther. 2018;26(7):1855-1866.

[198] Chen X, Yang S, Li S, et al. Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy. Mol Ther Oncolytics. 2021;21:144-157.

[199] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330.

[200] Dammeijer F, van Gulijk M, Mulder EE, et al. The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38(5):685-700.e8.

[201] Dong W, Wu X, Ma S, et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov. 2019;9(10):1422-1437.

[202] Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523-545.

[203] Single-cell proteomics: challenges and prospects. Nat Methods. 2023;20(3):317-318.

[204] Geiger T. Tackling tumor complexity with single-cell proteomics. Nat Methods. 2023;20(3):324-326.

[205] Mereu E, Lafzi A, Moutinho C, et al. Benchmarking single-cell RNA-sequencing protocols for cell atlas projects. Nat Biotechnol. 2020;38(6):747-755.

[206] Zhu C, Preissl S, Ren B. Single-cell multimodal omics: the power of many. Nat Methods. 2020;17(1):11-14.

[207] Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18(1):35-45.

[208] Chen GM, Chen C, Das RK, et al. Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov. 2021;11(9):2186-2199.

[209] Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184(13):3573-3587.e29.

[210] Heumos L, Schaar AC, Lance C, et al. Best practices for single-cell analysis across modalities. Nat Rev Genet. 2023;24(8):550-572.

[211] Xu L, Zou C, Zhang S, et al. Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol Oncol. 2022;15:87.

[212] Artyomov MN, Van den Bossche J. Immunometabolism in the single-cell era. Cell Metab. 2020;32(5):710-725.

[213] Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA A Cancer J Clin. 2021;71(4):333-358.

[214] Fan Y, Wang J, Wang Y, et al. Development and clinical validation of a novel 5 gene signature based on fatty acid metabolism-related genes in oral squamous cell carcinoma. Oxid Med Cell Long. 2022;2022:1-13.

[215] Tang L, Wei R, Chen R, et al. Establishment and validation of a cholesterol metabolism-related prognostic signature for hepatocellular carcinoma. Comput Struct Biotechnol J. 2022;20:4402-4414.

[216] Mou L, Pu Z, Luo Y, Quan R, So Y, Jiang H. Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis. Front Immunol. 2023;14:1036562.

[217] Wang H, Fu Y, Da BB, Xiong G. Single-cell sequencing identifies the heterogeneity of CD8+ T cells and novel biomarker genes in hepatocellular carcinoma. J Healthcare Eng. 2022;2022:8256314.

[218] Sun H, Long J, Zuo B, et al. Development and validation of a selenium metabolism regulators associated prognostic model for hepatocellular carcinoma. BMC Cancer. 2023;23(1):451.

[219] Zhang E, Ding C, Li S, et al. Polyamine metabolism patterns characterized tumor microenvironment, prognosis, and response to immunotherapy in colorectal cancer. Cancer Cell Int. 2023;23(1):96.

[220] Lin YS, Chen YC, Chen TE, et al. Probing folate-responsive and stage-sensitive metabolomics and transcriptional co-expression network markers to predict prognosis of non-small cell lung cancer patients. Nutrients. 2022;15(1):3.

[221] Yan X, Zhang X, Wu HH, et al. Novel T-cell signature based on cell pair algorithm predicts survival and immunotherapy response for patients with bladder urothelial carcinoma. Front Immunol. 2022;13:994594.

[222] Lin A, Qi C, Wei T, et al. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Briefings Bioinf. 2022;23(3):bbac129.

[223] Zhang J, Liu X, Huang Z, et al. T cell-related prognostic risk model and tumor immune environment modulation in lung adenocarcinoma based on single-cell and bulk RNA sequencing. Comput Biol Med. 2023;152:106460.

[224] Shi X, Dong A, Jia X, et al. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and therapeutic response in lung squamous cell carcinoma. Front Immunol. 2022;13:992990.

[225] Guo S, Liu X, Zhang J, et al. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer. Comput Biol Med. 2023;161:107066.

[226] Liu Y, Hu J, Liu D, et al. Single-cell analysis reveals immune landscape in kidneys of patients with chronic transplant rejection. Theranostics. 2020;10(19):8851-8862.

[227] Shi C, Qin K, Lin A, et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J Exp Clin Cancer Res. 2022;41(1):268.

[228] Jiang A, Luo P, Chen M, et al. A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. Cell Biosci. 2022;12(1):209.

[229] Caracciolo D, Riillo C, Arbitrio M, Di Martino MT, Tagliaferri P, Tassone P. Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment. Int J Cancer. 2020;147(10):2658-2668.

[230] Angelova M, Mlecnik B, Vasaturo A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175(3):751-765.e16.

[231] Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat Rev Immunol. 2018;18(11):671-688.

[232] Li H, Zhou K, Wang K, et al. A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy. Front Immunol. 2022;13:1040289.

[233] He L, Fan Y, Zhang Y, et al. Single-cell transcriptomic analysis reveals circadian rhythm disruption associated with poor prognosis and drug-resistance in lung adenocarcinoma. J Pineal Res. 2022;73(1):e12803.

[234] Fedele V, Melisi D. Permissive state of EMT: the role of immune cell compartment. Front Oncol. 2020;10:587.

[235] Jackstadt R, van Hooff SR, Leach JD, et al. Epithelial NOTCH signaling rewires the tumor microenvironment of colorectal cancer to drive poor-prognosis subtypes and metastasis. Cancer Cell. 2019;36(3):319-336.e7.

[236] Wu D, Hu L, Han M, et al. PD-1 signaling facilitates activation of lymphoid tissue inducer cells by restraining fatty acid oxidation. Nat Metab. 2022;4(7):867-882.

[237] Song M, Chan AT, Sun J. Influence of the gut microbiome, diet, and environment on risk of colorectal cancer. Gastroenterology. 2020;158(2):322-340.

[238] Makki K, Deehan EC, Walter J, Bäckhed F. The impact of dietary fiber on gut microbiota in host health and disease. Cell Host Microbe. 2018;23(6):705-715.

[239] Inamura K. Gut microbiota contributes towards immunomodulation against cancer: new frontiers in precision cancer therapeutics. Semin Cancer Biol. 2021;70:11-23.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.